Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Nkarta, Inc. (NKTX)

Coherus Oncology, Inc. and Nkarta, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Nkarta, Inc. are of similar size ($115.7M and $112.5M). Nkarta, Inc. has the higher net margin (0.00% vs −259.4%) and the lower return on invested capital (−127.2% vs 0.00%). Across the 15 metrics below, Nkarta, Inc. leads on 10 and Coherus Oncology, Inc. on 5.

Valuation

Metric CHRS NKTX Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 n/m 9.40
P/B 1.96 0.53 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.42 0.66
EV/Sales 4.44 n/m 9.02
Earnings yield (133.77%) (89.71%) (32.88%)
Free cash flow yield (156.84%) (72.03%) (23.13%)

Profitability

Metric CHRS NKTX Biotechnology median
Gross margin 68.94% 0.00% 68.51%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (38.76%) (51.96%)
Return on assets (41.90%) (29.86%) (46.06%)
Return on invested capital 0.00% (127.22%) 0.00%

Growth

Metric CHRS NKTX Biotechnology median
Revenue growth (TTM) 61.00% — 6.76%
EPS growth (last fiscal year) 472.00% 11.88% 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS NKTX Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 7.98 4.97
Net debt to EBITDA 0.76 2.35 1.01

Dividend

Metric CHRS NKTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS NKTX Biotechnology median
Market cap 115.71m 112.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack